120 related articles for article (PubMed ID: 33493795)
1. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.
Huang Y; Naidoo L; Zhang L; Carpp LN; Rudnicki E; Randhawa A; Gonzales P; McDermott A; Ledgerwood J; Lorenzo MMG; Burns D; DeCamp A; Juraska M; Mascola J; Edupuganti S; Mgodi N; Cohen M; Corey L; Andrew P; Karuna S; Gilbert PB; Mngadi K; Lazarus E
EBioMedicine; 2021 Feb; 64():103203. PubMed ID: 33493795
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.
Mgodi NM; Takuva S; Edupuganti S; Karuna S; Andrew P; Lazarus E; Garnett P; Shava E; Mukwekwerere PG; Kochar N; Marshall K; Rudnicki E; Juraska M; Anderson M; Karg C; Tindale I; Greene E; Luthuli N; Baepanye K; Hural J; Gomez Lorenzo MM; Burns D; Miner MD; Ledgerwood J; Mascola JR; Donnell D; Cohen MS; Corey L;
J Acquir Immune Defic Syndr; 2021 May; 87(1):680-687. PubMed ID: 33587510
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
Edupuganti S; Mgodi N; Karuna ST; Andrew P; Rudnicki E; Kochar N; deCamp A; De La Grecca R; Anderson M; Karg C; Tindale I; Greene E; Broder GB; Lucas J; Hural J; Gallardo-Cartagena JA; Gonzales P; Frank I; Sobieszczyk M; Gomez Lorenzo MM; Burns D; Anderson PL; Miner MD; Ledgerwood J; Mascola JR; Gilbert PB; Cohen MS; Corey L;
J Acquir Immune Defic Syndr; 2021 May; 87(1):671-679. PubMed ID: 33587505
[TBL] [Abstract][Full Text] [Related]
6. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
Ledgerwood JE; Coates EE; Yamshchikov G; Saunders JG; Holman L; Enama ME; DeZure A; Lynch RM; Gordon I; Plummer S; Hendel CS; Pegu A; Conan-Cibotti M; Sitar S; Bailer RT; Narpala S; McDermott A; Louder M; O'Dell S; Mohan S; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Mascola JR; Graham BS;
Clin Exp Immunol; 2015 Dec; 182(3):289-301. PubMed ID: 26332605
[TBL] [Abstract][Full Text] [Related]
8. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.
Huang Y; Zhang L; Eaton A; Mkhize NN; Carpp LN; Rudnicki E; DeCamp A; Juraska M; Randhawa A; McDermott A; Ledgerwood J; Andrew P; Karuna S; Edupuganti S; Mgodi N; Cohen M; Corey L; Mascola J; Gilbert PB; Morris L; Montefiori DC
Hum Vaccin Immunother; 2022 Dec; 18(1):1908030. PubMed ID: 34213402
[TBL] [Abstract][Full Text] [Related]
9. Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.
Takuva S; Karuna ST; Juraska M; Rudnicki E; Edupuganti S; Anderson M; De La Grecca R; Gaudinski MR; Sehurutshi A; Orrell C; Naidoo L; Valencia J; Villela LM; Walsh SR; Andrew P; Karg C; Randhawa A; Hural J; Gomez Lorenzo MM; Burns DN; Ledgerwood J; Mascola JR; Cohen M; Corey L; Mngadi K; Mgodi NM;
J Acquir Immune Defic Syndr; 2022 Apr; 89(4):405-413. PubMed ID: 34923559
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.
Huang Y; Zhang L; Ledgerwood J; Grunenberg N; Bailer R; Isaacs A; Seaton K; Mayer KH; Capparelli E; Corey L; Gilbert PB
MAbs; 2017 Jul; 9(5):792-800. PubMed ID: 28368743
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
[TBL] [Abstract][Full Text] [Related]
12. Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.
Li J; Nikanjam M; Cunningham CK; McFarland EJ; Coates EE; Houser KV; Lin BC; McDermott AB; Flach B; Gama L; Koup RA; Graham BS; Mascola JR; Ledgerwood JE; Capparelli EV
Clin Pharmacol Ther; 2021 Jan; 109(1):184-192. PubMed ID: 32866318
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD; Corey L; Montefiori D
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
[TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
[TBL] [Abstract][Full Text] [Related]
15. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.
Astronomo RD; Lemos MP; Narpala SR; Czartoski J; Fleming LB; Seaton KE; Prabhakaran M; Huang Y; Lu Y; Westerberg K; Zhang L; Gross MK; Hural J; Tieu HV; Baden LR; Hammer S; Frank I; Ochsenbauer C; Grunenberg N; Ledgerwood JE; Mayer K; Tomaras G; McDermott AB; McElrath MJ
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34166231
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.
McFarland EJ; Cunningham CK; Muresan P; Capparelli EV; Perlowski C; Morgan P; Smith B; Hazra R; Purdue L; Harding PA; Theron G; Mujuru H; Agwu A; Purswani M; Rathore MH; Flach B; Taylor A; Lin BC; McDermott AB; Mascola JR; Graham BS;
J Infect Dis; 2021 Dec; 224(11):1916-1924. PubMed ID: 34009371
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.
Seaton KE; Huang Y; Karuna S; Heptinstall JR; Brackett C; Chiong K; Zhang L; Yates NL; Sampson M; Rudnicki E; Juraska M; deCamp AC; Edlefsen PT; Mullins JI; Williamson C; Rossenkhan R; Giorgi EE; Kenny A; Angier H; Randhawa A; Weiner JA; Rojas M; Sarzotti-Kelsoe M; Zhang L; Sawant S; Ackerman ME; McDermott AB; Mascola JR; Hural J; McElrath MJ; Andrew P; Hidalgo JA; Clark J; Laher F; Orrell C; Frank I; Gonzales P; Edupuganti S; Mgodi N; Corey L; Morris L; Montefiori D; Cohen MS; Gilbert PB; Tomaras GD
EBioMedicine; 2023 Jul; 93():104590. PubMed ID: 37300931
[TBL] [Abstract][Full Text] [Related]
18. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
Gilbert PB; Juraska M; deCamp AC; Karuna S; Edupuganti S; Mgodi N; Donnell DJ; Bentley C; Sista N; Andrew P; Isaacs A; Huang Y; Zhang L; Capparelli E; Kochar N; Wang J; Eshleman SH; Mayer KH; Magaret CA; Hural J; Kublin JG; Gray G; Montefiori DC; Gomez MM; Burns DN; McElrath J; Ledgerwood J; Graham BS; Mascola JR; Cohen M; Corey L
Stat Commun Infect Dis; 2017 Jan; 9(1):. PubMed ID: 29218117
[TBL] [Abstract][Full Text] [Related]
19. Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
Magaret CA; Benkeser DC; Williamson BD; Borate BR; Carpp LN; Georgiev IS; Setliff I; Dingens AS; Simon N; Carone M; Simpkins C; Montefiori D; Alter G; Yu WH; Juraska M; Edlefsen PT; Karuna S; Mgodi NM; Edugupanti S; Gilbert PB
PLoS Comput Biol; 2019 Apr; 15(4):e1006952. PubMed ID: 30933973
[TBL] [Abstract][Full Text] [Related]
20. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
